Business Context and Reporting Period
Company: Charles River Laboratories International, Inc. (CRL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 27, 2026
Business Overview: A global non-clinical drug development partner providing research models, discovery and safety assessment services, and manufacturing solutions. The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 27, 2026 |
6 Months Ended June 27, 2026 |
|---|---|---|
| Total Revenue | $1,004,078 | $1,999,908 |
| Operating Income | $119,888 | $239,785 |
| Operating Margin | 11.9% | 12.0% |
| Net Income (Loss) Attributable to Common Shareholders | $(1,482) | $(16,325) |
| Diluted EPS | $(0.03) | $(0.34) |
| Operating Cash Flow | N/A | $220,802 |
| Free Cash Flow (Approx.) | N/A | $133,789 |
| Total Debt (Long-term + Current) | $2,626,611 | $2,626,611 |
| Cash and Cash Equivalents | $192,025 | $192,025 |
Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($87,013) for the six-month period.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 2.7% ($28.1M) in Q2 and 0.8% ($16.4M) in the first half of 2026 compared to the prior year. This was primarily driven by the divestiture of the CDMO business (Manufacturing segment) and European Discovery Services (DSA segment).
- Operating Income Expansion: Despite revenue declines, operating income increased 19.7% in Q2 and 37.2% in the first half. Margins improved due to a $38.5M gain on the sale of Wilmington, MA assets, lower accelerated amortization, and reduced legal costs compared to 2025.
- Net Loss: The company reported a net loss of $1.5M in Q2 and $16.3M for the six months, a sharp reversal from net income in the prior year. This was primarily caused by a $63.7M pre-tax loss on the CDMO and Cell Solutions divestiture recognized in Q2 (totaling $181.7M for the six months).
- Effective Tax Rate: The effective tax rate spiked to 101.4% in Q2 and 167.0% for the six months due to non-deductible transaction costs and tax effects related to divestitures.
Guidance, Outlook, and Risks
- Strategic Portfolio Changes: The company executed significant divestitures in May 2026, selling European Discovery Services to IQVIA and CDMO/Cell Solutions businesses to GI Partners. Conversely, it acquired a Cambodian NHP supplier ($507.3M preliminary price) and PathoQuest SAS ($67.6M) to strengthen supply chains and manufacturing testing.
- Cost Savings: Management expects to generate approximately $300 million in cumulative, annualized cost savings by the end of 2026 through workforce right-sizing and site optimization.
- Liquidity: The company maintains a $2.0 billion revolving credit facility with $1.12 billion drawn as of June 27, 2026. It also has $700 million remaining on a $1.0 billion stock repurchase program.
- Legal Contingencies: A securities class action regarding NHP importation disclosures was partially reversed on appeal in August 2025 and returned to district court. Two derivative lawsuits remain stayed pending the outcome of the class action. The company cannot estimate potential losses.
- Market Environment: Client spending remains cautious but improving, particularly in the DSA segment. DSA backlog increased slightly to $2.0 billion.
Investor Verification Checklist
- Divestiture Impact: Verify the long-term revenue impact of the CDMO and European Discovery divestitures versus the integration benefits of the Cambodian NHP acquisition.
- One-Time Gains/Losses: Assess the sustainability of operating margins after excluding the $38.5M asset sale gain and the $181.7M divestiture loss.
- Debt Levels: Monitor the increase in debt (from $2.14B to $2.62B) used to fund the Cambodian NHP acquisition and its impact on interest expense.
- Legal Exposure: Track the status of the securities class action appeal and potential financial exposure from NHP importation allegations.
- Restructuring Costs: Review the $54.6M in restructuring costs incurred in the first half of 2026 and the timeline for realizing the targeted $300M in annualized savings.